Journal of Clinical Oncology, Vol 15, 2322-2328, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease

DW Chan, RA Beveridge, H Muss, HA Fritsche, G Hortobagyi, R Theriault, D Kiang, BJ Kennedy and M Evelegh
Johns Hopkins Medical Institutions, Baltimore, MD 21287-7065, USA. dchan@pathlan.path.jhu.edu

PURPOSE: The Truquant BR radioimmunoassay (RIA) (Biomira Diagnostics Inc, Rexdale, Canada) uses the monoclonal antibody B27.29 to quantitate the MUC-1 gene product (CA 27.29 antigen) in serum. We evaluated CA 27.29 antigen in a controlled, prospective clinical trial for its ability to predict relapse in stage II and stage III breast cancer patients. PATIENTS AND METHODS: Over a 2-year period, 166 patients who had completed therapy for stage II (80.1%) or III (19.9%) breast cancer and were clinically free of disease were serially tested for CA 27.29 antigen levels. The study was double-masked and cancer recurrence was documented based on clinical findings. Patients with two consecutive CA 27.29 antigen test results above the upper limit of normal were considered positive. RESULTS: The Truquant BR RIA had a sensitivity of 57.7%, specificity of 97.9%, positive predictive value of 83.3%, and negative predictive value of 92.6%. The recurrence rate was 15.7%. A Cox regression analysis showed that the only variable to correlate with recurrent disease was the CA 27.29 antigen test result. Patients with a positive test result had increased odds of having a recurrence (odds ratio, 6.8; P < .00001). The test was effective in predicting recurrence in patients with both distant and locoregional disease. In a subgroup of patients with bone pain, CA 27.29 antigen level was found to identify reliably patients who would subsequently develop recurrent disease. CONCLUSION: These data demonstrate that the Truquant BR RIA can be used as an aid to predict recurrent breast cancer in patients with stage II and III disease.

This article has been cited by other articles:

				C. M. Sturgeon, M. J. Duffy, U.-H. Stenman, H. Lilja, N. Brunner, D. W. Chan, R. Babaian, R. C. Bast Jr., B. Dowell, F. J. Esteva, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers Clin. Chem., December 1, 2008; 54(12): e11 - e79. [Abstract] [Full Text] [PDF]

				J. Li, Z. Zhang, J. Rosenzweig, Y. Y. Wang, and D. W. Chan Proteomics and Bioinformatics Approaches for Identification of Serum Biomarkers to Detect Breast Cancer Clin. Chem., August 1, 2002; 48(8): 1296 - 1304. [Abstract] [Full Text] [PDF]

				G. Soletormos, P. H. Petersen, and D. Nielsen Computer-simulated Tumor-Marker Data Used to Compare Progression Criteria for Cytokeratin Tissue Polypeptide Antigen in Metastatic Breast Cancer Clin. Chem., November 1, 2001; 47(11): 2035 - 2037. [Full Text] [PDF]

				R. C. Bast Jr, P. Ravdin, D. F. Hayes, S. Bates, H. Fritsche Jr, J. M. Jessup, N. Kemeny, G. Y. Locker, R. G. Mennel, and M. R. Somerfield 2000 Update of Recommendations for the Use of Tumor Markers in Breast and Colorectal Cancer: Clinical Practice Guidelines of the American Society of Clinical Oncology J. Clin. Oncol., March 15, 2001; 19(6): 1865 - 1878. [Abstract] [Full Text] [PDF]

				S. P. Treon, P. Maimonis, D. Bua, G. Young, N. Raje, J. Mollick, D. Chauhan, Y.-T. Tai, T. Hideshima, Y. Shima, et al. Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma Blood, November 1, 2000; 96(9): 3147 - 3153. [Abstract] [Full Text] [PDF]

				G. Soletormos, P. Hyltoft Petersen, and P. Dombernowsky Progression Criteria for Cancer Antigen 15.3 and Carcinoembryonic Antigen in Metastatic Breast Cancer Compared by Computer Simulation of Marker Data Clin. Chem., July 1, 2000; 46(7): 939 - 949. [Abstract] [Full Text] [PDF]

				T. Gilewski, S. Adluri, G. Ragupathi, S. Zhang, T.-J. Yao, K. Panageas, M. Moynahan, A. Houghton, L. Norton, and P. O. Livingston Vaccination of High-Risk Breast Cancer Patients with Mucin-1 (MUC1) Keyhole Limpet Hemocyanin Conjugate plus QS-21 Clin. Cancer Res., May 1, 2000; 6(5): 1693 - 1701. [Abstract] [Full Text]

				M. Gion, R. Mione, A. E. Leon, and R. Dittadi Comparison of the Diagnostic Accuracy of CA27.29 and CA15.3 in Primary Breast Cancer Clin. Chem., May 1, 1999; 45(5): 630 - 637. [Abstract] [Full Text] [PDF]

				T. J. Smith, N. E. Davidson, D. V. Schapira, E. Grunfeld, H. B. Muss, V. G. Vogel III, and M. R. Somerfield American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines J. Clin. Oncol., March 1, 1999; 17(3): 1080 - 1080. [Abstract] [Full Text] [PDF]

				C. D. Cheli, D. L. Morris, L. Kish, J. Goldblatt, I. Neaman, W. J. Allard, K. K. Yeung, A. H. B. Wu, R. Moore, D. W. Chan, et al. Multicenter evaluation of the Bayer Immuno 1(TM) CA 15-3(TM) assay Clin. Chem., April 1, 1998; 44(4): 765 - 772. [Abstract] [Full Text] [PDF]